SPD 473

Drug Profile

SPD 473

Alternative Names: BTS 74398

Latest Information Update: 05 Aug 2004

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Major depressive disorder; Parkinson's disease

Most Recent Events

  • 30 Jul 2004 Discontinued - Phase-II for Attention-deficit hyperactivity disorder in Europe (unspecified route)
  • 02 Oct 2002 Discontinued - Phase-II for Depression in Europe (unspecified route)
  • 02 Oct 2002 Discontinued - Phase-II for Depression in Southern Africa (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top